Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GTB-7550
- Development stage
- Preclinical
- Lead developer
- GT Biopharma
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Parenteral
01
Overview
GTB-7550 is a tri-specific killer engager (TriKE) developed by GT Biopharma for the treatment of CD19-positive lymphoid malignancies and autoimmune diseases. It is a recombinant fusion protein composed of three functional domains: - A camelid nanobody that binds to the CD16 receptor on natural killer (NK) cells, - The single-chain variable fragment (scFv) of an anti-CD19 antibody targeting B cells, - Human wild-type interleukin 15 (IL-15), which stimulates NK cell proliferation and activation. The mechanism leverages antibody-dependent cellular cytotoxicity by engaging NK cells via CD16, directing them to kill CD19-expressing malignant or autoreactive B cells. Preclinical studies have demonstrated activity against lymphoma and chronic lymphocytic leukemia models as well as potential in autoimmune disease settings such as lupus. As of late 2024, it remains in preclinical development with plans for clinical material production and regulatory submission after 2026[1][2][3][7][8].
- Brand names
- GTB-7550 TriKEGTB7550 TriKEGTB 7550 TriKE
- Other names
- CAM-161519CAM161519CAM 161519GTB 7550GTB7550GTB-7550GTB-7750 TriKEGTB7750 TriKEGTB 7750 TriKE
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)CD19 (B lymphocyte antigen CD19)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on GTB-7550.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GTB-7550.